P2Y13 Receptor Regulates HDL Metabolism and Atherosclerosis In Vivo

• Marine Goffinet,

  Affiliation Cerenis Therapeutics SA, Labege, France

  ⨯
• Claudine Tardy,

  Affiliation Cerenis Therapeutics SA, Labege, France

  ⨯
• Nadia Boubekeur,

  Affiliation Cerenis Therapeutics SA, Labege, France

  ⨯
• Guy Cholez,

  Affiliation Cerenis Therapeutics SA, Labege, France

  ⨯
• Alice Bluteau,

  Affiliation Cerenis Therapeutics SA, Labege, France

  ⨯
• Daniela C. Oniciu,

  Affiliation Cerenis Therapeutics SA, Labege, France

  ⨯
• Narendra D. Lalwani,

  Affiliation Cerenis Therapeutics Inc., Ann Arbor, Michigan, United States of America

  ⨯
• Jean-Louis H. Dasseux,

  Affiliation Cerenis Therapeutics SA, Labege, France

  ⨯
• Ronald Barbaras ,

  * E-mail: barbaras@cerenis.com

  Affiliation Cerenis Therapeutics SA, Labege, France

  ⨯
• Rudi Baron

  Affiliation Cerenis Therapeutics SA, Labege, France

  ⨯